Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka. This expansion significantly increases the company's addressable market to an estimated $13.0 billion, according to the press release.
The expansion supports the planned commercialization of the CoSara PCR Pro point-of-care platform and the SARAGENE product line, subject to regulatory approvals. The company is building regional distribution channels and positioning for broader deployment of its molecular diagnostics solutions. Co-Diagnostics develops, manufactures and markets state-of-the-art diagnostics technologies, utilizing tests designed using the detection and/or analysis of nucleic acid molecules.
This strategic move allows Co-Diagnostics to tap into new markets with high demand for diagnostic solutions. The inclusion of Bangladesh, Pakistan, Nepal and Sri Lanka provides a larger customer base for the company's innovative molecular diagnostics tools. The company's technologies are also used to design specific tests for its Co-Dx PCR at-home and point-of-care platform, which is subject to regulatory review and not currently for sale.
For more information about Co-Diagnostics, visit https://co-dx.com/. The full press release can be viewed at https://ibn.fm/2aATV.
This expansion marks a significant milestone for Co-Diagnostics as it seeks to establish a strong presence in the South Asian diagnostic market. With an estimated $13 billion addressable market, the company is poised to leverage its proprietary technology to address the growing need for accurate and accessible molecular diagnostics in the region.
